Case study

Webinar: #Rethink your HCP strategy

March 2022 by Thomas Kofoed

Rethink your HCP strategy

Do you have problems developing a process-specific HCP ELISA? It's time to #rethink your strategy!

With mass spectrometry-based HCP analysis – now available under GMP conditions - you have access within weeks to a method with several advantages:

✔️ High coverage and sensitivity
✔️ It is suitable for Sf9, A549, HEK, E. coli, and Vero cell lines
✔️ You can demonstrate comparability between batches
✔️ It costs a fraction of the developing a process-specific ELISA
✔️ We can set up the method for your process within weeks.

The method is available for full validation following ICH guidelines and is thus appropriate for release tests for phase 3 and commercial production.

With the introduction of MS-based HCP analysis under GMP, you can go from pre-clinical to release test with one robust, flexible, and highly sensitive assay.

Talk to us

Whatever protein-related challenge or question you may have, we would love to help. Our experts can help you decide on the best analytical approach for your project by email or online meeting - providing advice without obligation.

I would like an
This field is for validation purposes and should be left unchanged.